Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers

Objectives: This phase III study assessed the safety and immunogenicity of MenACWY-CRM, a quadrivalent meningococcal conjugate vaccine, administered with routine vaccines starting at 2 months of age. Methods: Healthy infants received MenACWY-CRM in a two- or three-dose primary infant series plus a...

Full description

Bibliographic Details
Main Authors: Miguel Tregnaghi, Pio Lopez, Daniel Stamboulian, Gabriela Graña, Tatjana Odrljin, Lisa Bedell, Peter M. Dull
Format: Article
Published: Elsevier 2014-09-01
Series:International Journal of Infectious Diseases
Online Access: